Intuitive Surgical (ISRG) reported robust second-quarter 2026 financial results, driven by significant growth in both its core da Vinci and newer Ion robotic surgery platforms. Total revenue reached $2.89 billion, representing a 19% year-over-year increase from the prior year's $2.44 billion. This expansion was fueled...
Bullish Signals
Revenue grew 19% year-over-year to $2.89 billion.
Instruments revenue increased 18% to $1.73 billion.
Ion procedure volume surged 36%.
GAAP income from operations rose 31% to $972 million.
Intuitive Surgical announced its first quarter 2026 financial results today, reporting significant growth across its global portfolio of robotic-assisted surgery technologies. Worldwide procedures combining both da Vinci and Ion systems grew approximately 17% compared to the first quarter of 2025. The company placed 431 da...
Bullish Signals
Worldwide procedures grew 17%; da Vinci up 16%, Ion surged 39%.
Placed 431 da Vinci systems (+64 YoY) and 52 Ion systems (vs. 49).
First quarter revenue rose 23% to $2.77B, vs. $2.25B last year.
GAAP net income reached $822M ($2.28/share), up from $698M ($1.92/share).
Non-GAAP net income hit $901M ($2.50/share), vs. $662M ($1.81/share) last year.
Instruments revenue grew 23% to $1.69B, driven by procedure volume growth.
Installed base expanded: da Vinci count now 11,395 systems; Ion at 1,041.
Repurchased 2.3M shares for $1.1B, showing confidence in long-term value.
Bearish Signals
Excess tax benefits fell $72M YoY to $73M ($0.20/share).
Cash dropped $1.05B in Q1 due to buybacks and M&A.
Aggressive stock repurchases reduce liquidity for growth.
Margins hit 67.5%β68.5%, including 1% tariff impact.
Intuitive Surgical reported robust third-quarter financial performance for the period ended September 30, 2026, driven by significant growth in its core robotic surgery business. Total revenue surged 22% year-over-year to reach $3.05 billion, fueled by a 15% increase in worldwide procedures across both da Vinci...
Bullish Signals
Revenue rose 22% to $3.05B driven by procedure volume.
Bearish Signals
Antitrust charge reduced GAAP net income to $523 million.
Intuitive Surgical (ISRG) shares fell 37% to $355 following Q2 earnings, where the company beat revenue estimates with 19% growth and non-GAAP EPS of $2.80. Despite the financial beat, management cut full-year procedure growth guidance for the da Vinci system to a range of 13.5%-15.5%,...
Bullish Signals
Revenue grew 19% YoY to $2.89 billion.
Non-GAAP EPS of $2.80 beat consensus.
$379 million stock repurchase executed in Q2.
$8.6 billion cash reserves on balance sheet.
International procedures surged 21% in Q2.
Bearish Signals
Guidance cut to 13.5%-15.5%, down from 18% in 2025.
U.S. da Vinci growth slowed to 12% in Q2.
Bariatric cases declined due to GLP-1 drug competition.
Tariffs in Mexico, Germany, and China compress valuation.
Stock fell 37% YTD despite underlying business growth.
Intuitive Surgical (ISRG) reported standout Q1 2023 results, beating analyst estimates with revenue of $1.70 billion, a 14% year-over-year increase, and adjusted earnings of $1.23 per share versus the expected $1.20. The surge was driven by a 26% jump in procedure volumes as hospitals cleared...
Bullish Signals
Revenue up 14% to $1.70 billion, beating estimates.
Intuitive Surgical reported its Q1 earnings with a notably upbeat tone, driven by strong revenue growth of 23% year over year to $2.77 billion. Recurring revenue increased 23% to $2.4 billion, now representing 86% of total sales, which underscores the company's annuity-like business model favored...
Bullish Signals
Revenue rose 23% YoY to $2.77B.
Recurring revenue reached $2.4B, up 23%, representing 86% of sales.
Total procedures climbed 17% YoY; da Vinci grew 16% to 847K units.
Ion procedures jumped 39% YoY to 43K systems.
Company placed 431 da Vinci systems, including 232 da Vinci 5 units.
Non-GAAP net income increased to $901M versus $662M prior year.
Single-Port procedures surged 68% YoY; U.S. system utilization up 22%.
Ion platform saw 39% growth with 79% diagnostic yield on lung cases.
Operating margin hit 39%; gross margin improved to 67.8%.
Cyber incident had no operational impact.
Bearish Signals
China procedure growth lags due to low tenders, pricing pressures, and competition.
China regulatory clarity not expected until 2027, remaining a long-term drag.
Japan growth below norms from fewer system placements in 2025.
U.S. da Vinci bariatric procedures down ~10% from GLP-1 drug impact.
Cyber incident exposed customer/employee data despite containment efforts.
Higher freight, chip, oil, and tariff costs weigh on margins by year end.
Tariffs alone may cut gross margin ~100 basis points later in the year.
Intuitive Surgical (ISRG) saw its stock rise approximately 7% in intraday trading following the release of better-than-expected Q1 earnings results, with revenue increasing by roughly 23% year-over-year and non-GAAP net income climbing around 36% year-over-year. The company's performance exceeded consensus estimates, prompting Wall Street analysts...
Bullish Signals
Intuitive Surgical stock surged ~7% intraday, biggest gain since October.
Intuitive Surgical (ISRG) reported second-quarter revenue of $2.89 billion and adjusted EPS of $2.80, both beating Wall Street estimates. Despite the financial beat, shares fell 11% as management signaled a deceleration in growth trajectory and announced plans to cut prices on key instrument lines starting...
Bullish Signals
Beat Q2 revenue and EPS estimates.
Worldwide da Vinci procedures grew 16% YoY.
Ramping da Vinci 5; 246 of 468 placed.
New FDA clearance opens 160k annual procedure opportunity.
International expansion diversifies revenue streams.
Intuitive Surgical (ISRG) is preparing to release its Q2 2026 earnings results after market close on Thursday, July 16th. Analysts project the company will report earnings per share of $2.48 and revenue of $2.8249 billion for the quarter. The upcoming earnings call is scheduled for...
Bullish Signals
Beat estimates with $2.50 EPS vs $2.08 consensus.
Revenue grew 23.0% year-over-year last quarter.
Net margins remained healthy at 28.15%.
Analysts project $9 and $10 EPS for next two years.
Bearish Signals
Director Amy Ladd sold 119 shares, reducing position by nearly 50%.
EVP Gary Loeb sold 400 shares, decreasing ownership by 6.54%.
Insiders collectively sold over $3 million in 7,169 shares last three months.
Intuitive Surgical (ISRG), Medtronic (MDT), and Stryker (SYK) are identified as key players where surgical robotics integrates with artificial intelligence capabilities. Intuitive Surgical reported Q1 FY26 non-GAAP EPS of $2.50, beating estimates by 18.66%, with revenue reaching $2.77 billion. The company's installed base of da...
Bullish Signals
Intuitive Surgical beat EPS estimates by 18.66% with Q1 FY26 non-GAAP EPS of $2.50.
Revenue jumped 22.96% YoY to $2.77B, driven by $1.69B high-margin Instruments & Accessories.
Installed base rose 12% for da Vinci systems and 22% for Ion platforms.
Ion system procedure volume surged 39% while operating income increased 47.95%.
Company holds robust $7.98B cash after repurchasing 2.3 million shares.
FY26 guidance projects 13.5% to 15.5% da Vinci procedure growth.
Medtronic beat with Q3 FY26 revenue of $9.017B and EPS of $1.36.
Bearish Signals
Missed Q1 FY26 EPS estimates and revenue expectations.
Cybersecurity incident and $118M charges compressed operating margins.
Tariff exposure in Mexico, Germany, China creates margin headwinds.
Intuitive Surgical (ISRG) stock surged 7.2% on Wednesday to close at $483.62 after the company reported stronger-than-expected first-quarter results and raised its full-year procedural outlook. The medical technology giant beat estimates with quarterly sales growing 23% year-over-year to $2.77 billion, compared to analyst expectations of...
Bullish Signals
Intuitive Surgical (ISIR) sales grew 23% to $2.77 billion.
EPS reached $2.50, beating expectations of $2.12 by 38%.
Full-year procedure volume guidance raised to 13.5%-15.5% growth.
Q1 procedures surged 17%, exceeding the 14.5% expectation.
Da Vinci 5 utilization rose 11% with strong European demand.
Ion robotic systems saw a robust 39% procedure growth.
431 Da Vinci systems placed, up 17% from prior year.
System placement revenue jumped 24.5% to $651 million.
Intuitive Surgical (ISRG) sees its fair value estimate rise from approximately US$476.34 to roughly US$486.57 per share, driven by a mixed but ultimately bullish analyst narrative following Q3 results. Major financial institutions including BofA, Barclays, JPMorgan, and Leerink have lifted their price targets, citing robust...
Bullish Signals
Analysts lifted targets citing solid Q3 results and strong system placement strength.
Robust da Vinci 5 placements support future expansion outside the U.S.
Q3 revenue of US$3.05B and EPS of US$3.00 beat consensus.
Capital demand supports growth runway in ambulatory surgery centers.
Bearish Signals
Slowing U.S. procedure growth concerns analysts.
Policy volume pressures weigh on near-term performance.
Intuitive Surgical reported strong third-quarter financial results driven by significant growth in its core surgical platforms, though reported earnings were impacted by a proposed antitrust settlement. The company posted revenue of USD 3.05 billion, representing a 22 percent year-over-year increase, with worldwide procedures on the...
Intuitive Surgical reported robust third-quarter financial performance driven by significant growth in both system placements and procedure volumes. Revenue for the quarter ended September 30 reached $3.05 billion, representing a 22% year-over-year increase from the prior period. This growth was fueled by a 14% rise...
Bullish Signals
Revenue grew 22% YoY to $3.05B.
Non-GAAP net income rose to $1.05B.
Placed 546 da Vinci systems in Q3.
Ion procedures climbed 31% year-over-year.
Instruments revenue increased 18% to $1.80B.
Bearish Signals
GAAP net income fell $523M due to $450M antitrust charge.
Intuitive Surgical (ISRG) shares fell 7.5% in pre-market trading following its third-quarter 2026 earnings report, despite adjusted EPS of $3.00 and revenue of $3.05 billion both beating analyst estimates. The stock decline was primarily driven by a $450 million pre-tax charge related to the settlement...
Bullish Signals
Earnings of $3.00 beat consensus of $2.65.
Bearish Signals
$450M antitrust charge significantly reduced GAAP net income.
Intuitive Surgical reported strong second-quarter financial results, with revenue reaching USD 2.89 billion, representing a 19 percent year-over-year increase. GAAP net income for the quarter was USD 818.10 million, up from USD 658.00 million in the same period last year. The company's stock traded at...
Intuitive Surgical (NASDAQ:ISRG) reported strong fiscal Q2 results with revenue increasing 19% year-over-year to $2.89 billion, driven by a 15% rise in worldwide da Vinci procedure volumes. The company's recurring revenue model proved resilient as instruments and accessories revenue grew 18% to $1.73 billion, reflecting...
Bullish Signals
Revenue grew 19% YoY driven by expanding procedure volumes.
Bearish Signals
Non-GAAP gross margins expected to decline to 68-69% in fiscal 2026.
Additional tariffs could materially affect 2026 financial results.
Worldwide da Vinci procedure growth slowed to 15% in Q2.
Intuitive Surgical reported robust financial performance for the second quarter of 2026, generating USD 2.89 billion in revenue. This figure represents an 18.5 percent increase compared to the same period in the prior year and exceeded analyst estimates by 2.6 percent, indicating strong commercial execution...
Bullish Signals
Revenue grew 18.5% YoY to $2.89B in Q2 2026.
Beat estimates by 2.6%, exceeding market expectations.
Intuitive Surgical (ISRG) shares edged higher on September 17, 2026, closing at USD 383.54 on the Nasdaq following a significant regulatory milestone and strong quarterly performance. The company received CE mark approval in Europe for its da Vinci SP single-port robotic system to perform transvaginal...
Bullish Signals
da Vinci SP got CE mark for transvaginal procedures in Europe.
Bearish Signals
Shares fell 32.3% YTD in 2026 below analyst valuations.
VP sold 1,089 shares worth USD 407,765 on Sept 17, 2026.
HSBC downgraded Intuitive Surgical (NASDAQ:ISRG) from a Buy to a Hold rating, setting a $391 target price. This move follows a series of recent analyst adjustments, including Sanford Bernstein lowering its target to $685 and Jefferies reducing its objective to $515, though the consensus remains...
Bullish Signals
Revenue hit $2.89B, beating estimates of $2.83B.
EPS reached $2.80, surpassing the $2.48 consensus.
We use cookies to run the site and, only if you allow it, for live chat, analytics, personalization and ad measurement.
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Offer a live chat with our team (Enuchat, optional)
Measure audience engagement and site statistics to understand how our services are used (Google Analytics, optional)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
Measure how our ads on Facebook and Instagram perform, including whether a visit leads to a confirmed sign-up, matched to your Facebook or Instagram account using hashed contact details you enter (Meta Pixel, optional)
Optional cookies are only set if you allow them. You can accept all, reject all or choose per category, and change your choice at any time via the "Manage Cookies" link in the footer. Google and Meta may process this data in the USA. More in our Privacy Policy.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Functional cookies
Show the live chat button so you can message our team. The Enuchat chat widget stores a visitor ID in your browser and sends your chat messages to Enuchat. When this is off, the chat is not loaded.
Cookie
Purpose
Duration
enuchat_visitor_id
Keeps your chat conversation linked to this browser (Enuchat, browser storage)
Until you clear it or turn this off
Analytics cookies
Help us understand how visitors use our website with Google Analytics, provided by Google LLC. Google receives pages visited, device data and an IP address, and may process them in the USA. If you also allow marketing cookies, the Google tag can detect contact details you enter or see on our pages, such as your email address, phone number, name or address, hash them before sending and pass them to Google so it can match your visits to a Google account for measuring our ads. Hashed details are still personal data. See how Google uses information from sites that use its services.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
1 year
Marketing cookies
Let Meta (Facebook and Instagram) measure how our ads perform, using the Meta Pixel. Meta Platforms Ireland Ltd. receives the pages you visit and, when you confirm the email address of a new account, a "completed registration" event, together with browser identifiers and your IP address. Meta's automatic advanced matching also reads contact details you type into forms on our site, such as your email address or name, hashes them in your browser and sends them with these events so Meta can match them to a Facebook or Instagram account. Hashed details are still personal data. These events are sent from your browser and may also be forwarded to Meta through Meta's Conversions API Gateway. Our own server also sends page visits and completed-registration events directly to Meta's Conversions API, with your IP address, browser user agent and Meta browser identifiers, so Meta can count it once. To help Meta match these visits, your browser and our server also send a random visitor ID from our own cookie and, if you are signed in, your account ID, your confirmed email address and the name, city, postal code and country saved in your profile, all hashed first. We and Meta are joint controllers for collecting and sending this data, and Meta's further use, which may include processing in the USA, is described in the Meta Privacy Policy. When this is off, the Meta Pixel is not loaded and no page visit or registration event is sent to Meta. Together with analytics cookies, this choice also lets Google receive hashed contact details, as described under Analytics cookies.
Cookie
Purpose
Duration
_fbp
Identifies browsers for Meta ad measurement (Meta Pixel)
3 months
_fbc
Stores the Meta ad click that brought you here (Meta Pixel)
3 months
_bes_meid
Random visitor ID, sent to Meta only hashed, so your visits can be matched (Meta Pixel and Conversions API)